Rallybio (RLYB) Non Operating Income (2020 - 2026)
Rallybio (RLYB) posted Non Operating Income of $455000.0 for Q1 2026, down 18.75% sequentially from $560000.0 in Q4 2025, and down 44.38% YoY from $818000.0 in Q1 2025.
Rallybio (RLYB) Non Operating Income (2020 - 2026) Analysis & Trends
Rallybio has reported Non Operating Income for 7 years, with the latest figure at $455000.0 in Q1 2026.
- Quarterly Non Operating Income fell 44.38% year-over-year to $455000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.6 million (up 467.4% YoY) and the FY2025 annual result came in at $25.0 million, up 403.23% from the prior year.
- Non Operating Income eased to $455000.0 in Q1 2026 per RLYB's latest filing, from $560000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $22.9 million in Q3 2025 and troughed at $210000.0 in Q1 2022.
- A 5-year average of $2.3 million and a median of $1.1 million in 2022 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1754.57% in 2025, down 50.16% in 2025.
- Over 5 years, Non Operating Income stood at $1.1 million in 2022, then jumped by 34.57% to $1.5 million in 2023, then sank by 32.97% to $994000.0 in 2024, then sank by 43.66% to $560000.0 in 2025, then fell by 18.75% to $455000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $455000.0, $560000.0, and $22.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 50.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.64 Mn |
| Mar 31, 2026 | 455,000.00 |
| Dec 31, 2025 | 560,000.00 |
| Sep 30, 2025 | 22.94 Mn |
| Jun 30, 2025 | 641,000.00 |
| Mar 31, 2025 | 818,000.00 |
| Dec 31, 2024 | 994,000.00 |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Jun 30, 2023 | 1.67 Mn |
| Mar 31, 2023 | 1.62 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 623,000.00 |
| Jun 30, 2022 | 370,000.00 |
| Mar 31, 2022 | 210,000.00 |
| Dec 31, 2021 | 121,000.00 |
| Sep 30, 2021 | 117,000.00 |